Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allena Pharmaceuticals, Inc.ALNA · Entity 130904 | Director | June 03, 2021 | June 04, 2021 |
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | Director | June 08, 2026 | June 10, 2026 |
| COMPASS Pathways plcCMPS · Entity 4567 | Director | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allena Pharmaceuticals, Inc.
Report date June 03, 2021 · Filed June 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.14 · Expires 2031-06-02 | Direct | 37,000 |
Reported balance
After 2021-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-03 · Grant · Acquired 37,000 · Balance 37,000 F1: Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of stockholders.
COLLEGIUM PHARMACEUTICAL, INC
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 112,483 |
Reported balance
After 2026-06-08 transaction · row 1
1 source rowRow 1 · 2026-06-08 · Exercise / conversion · Acquired 8,700 · Balance 112,483 |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $16.49 · Expires 2026-06-09 | Direct | 0 |
Reported balance
After 2026-06-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-08 · Exercise / conversion · Disposed 8,700 · Balance 0 F1: The option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is fully vested and exercisable.
COMPASS Pathways plc
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.85 · Expires 2036-05-26 | Direct | 30,158 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 30,158 · Balance 30,158 F1: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027.
F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Past disclosures · reporting ended (5)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMAG PHARMACEUTICALS, INC.
Report date November 16, 2020 · Filed November 17, 2020
Section 16 reporting ended · disclosed 2020-11-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 1
1 source rowRow 1 · 2020-11-16 · Disposition to issuer · Disposed 41,473 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-16 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-16 · Disposition to issuer · Disposed 950 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-16 · Disposition to issuer · Disposed 3,800 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-16 · Disposition to issuer · Disposed 3,800 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-16 · Disposition to issuer · Disposed 7,600 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-11-16 · Disposition to issuer · Disposed 3,575 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-11-16 · Disposition to issuer · Disposed 12,787 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-11-16 · Disposition to issuer · Disposed 10,110 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-11-16 · Disposition to issuer · Disposed 7,543 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-11-16 · Disposition to issuer · Disposed 17,326 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-11-16 · Disposition to issuer · Disposed 21,289 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.
F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.
F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
ELI LILLY & Co
Report date December 31, 2009 · Filed February 03, 2010
Section 16 reporting ended · disclosed 2010-02-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 96,495 |
Ending reported balance
After 2009-12-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2009-05-05 · Gift · Disposed 5,259 · Balance 96,915 Row 2 · 2009-12-07 · Gift · Disposed 420 · Balance 96,495 |
| Common StockSEC Table I · non-derivative | Indirectby daughter | 3,806 |
Reported balance
After 2009-05-05 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2009-05-05 · Gift · Acquired 751 · Balance 3,806 F1: Reporting person disclaims beneficial ownership of these shares. |
| Common StockSEC Table I · non-derivative | Indirectby son | 3,806 |
Reported balance
After 2009-05-05 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2009-05-05 · Gift · Acquired 751 · Balance 3,806 F1: Reporting person disclaims beneficial ownership of these shares. |
| Common StockSEC Table I · non-derivative | Indirectby wife | 16,145 |
Reported balance
After 2009-05-05 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2009-05-05 · Gift · Acquired 3,757 · Balance 16,145 F1: Reporting person disclaims beneficial ownership of these shares. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 3,249 |
Reported balance
Holding disclosure · report date 2009-12-31 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 3,249 |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting person disclaims beneficial ownership of these shares.
Horizon Therapeutics Public Ltd Co
Report date October 06, 2023 · Filed October 06, 2023
Section 16 reporting ended · disclosed 2023-10-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 1
1 source rowRow 1 · 2023-10-06 · Disposition to issuer · Disposed 100,959 · Balance 0 F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2023-10-06 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-10-06 · Disposition to issuer · Disposed 18,655 · Balance 0 F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.53 · Expires 2025-05-05 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-10-06 · Disposition to issuer · Disposed 8,548 · Balance 0 F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2: The Option (as defined in footnote 3 to this Form 4) is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.12 · Expires 2027-05-02 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-10-06 · Disposition to issuer · Disposed 31,153 · Balance 0 F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2: The Option (as defined in footnote 3 to this Form 4) is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.87 · Expires 2028-05-02 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-10-06 · Disposition to issuer · Disposed 32,161 · Balance 0 F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2: The Option (as defined in footnote 3 to this Form 4) is fully vested. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2024-07-27 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-10-06 · Disposition to issuer · Disposed 4,016 · Balance 0 F4: Each RSU (as defined in footnote 6 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F6: Reflects the disposition of Issuer's restricted stock unit award (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration. F5: The Ordinary Shares subject to the RSUs vest on July 27, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").
F2: The Option (as defined in footnote 3 to this Form 4) is fully vested.
F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option.
F4: Each RSU (as defined in footnote 6 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer.
F5: The Ordinary Shares subject to the RSUs vest on July 27, 2024.
F6: Reflects the disposition of Issuer's restricted stock unit award (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration.
INTERCEPT PHARMACEUTICALS, INC.
Report date November 08, 2023 · Filed November 13, 2023
Section 16 reporting ended · disclosed 2023-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2023-11-08 · Other · Disposed 23,645 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2023-11-08 · Disposition to issuer · Disposed 8,111 · Balance 0 F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $17.08 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-11-08 · Disposition to issuer · Disposed 12,089 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $16.82 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-11-08 · Disposition to issuer · Disposed 12,790 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $9.17 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-11-08 · Disposition to issuer · Disposed 12,547 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $183.62 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-11-08 · Disposition to issuer · Disposed 3,500 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $145.22 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-11-08 · Disposition to issuer · Disposed 1,598 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $122.01 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-11-08 · Disposition to issuer · Disposed 2,036 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $85.12 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-11-08 · Disposition to issuer · Disposed 2,748 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $82.25 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-11-08 · Disposition to issuer · Disposed 2,174 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $72.74 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-11-08 · Disposition to issuer · Disposed 2,966 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.
F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Vitae Pharmaceuticals, Inc
Report date October 25, 2016 · Filed October 25, 2016
Section 16 reporting ended · disclosed 2016-10-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2024-09-23 | Direct | 0 |
Reported balance
After 2016-10-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-10-25 · Disposition to issuer · Disposed 17,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F2: This option, which provided for vesting in three equal annual installments following on September 24, 2014, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.43 · Expires 2025-05-27 | Direct | 0 |
Reported balance
After 2016-10-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-10-25 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3: This option, which is fully vested, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.62 · Expires 2026-05-25 | Direct | 0 |
Reported balance
After 2016-10-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-10-25 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F4: This option, which provided for vesting in four equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option.
F2: This option, which provided for vesting in three equal annual installments following on September 24, 2014, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
F3: This option, which is fully vested, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
F4: This option, which provided for vesting in four equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2006 Filed Feb 14, 2006 21:59 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantEmployee stock option 2/06 (right to buy) · Derivative | 45,181 | $0.00 Strike: $56.18 | $0.00 |
DisclosureSEC source: 0001209191-06-010472 · doc4.xml · derivative · entry 1 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,181 Underlying: Common Stock · 45,181 shares Expires 2016-02-09 Read SEC document |
| February 01, 2006 Filed Feb 3, 2006 13:10 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 1,778 | $56.62 | $100,670.36 |
DisclosureSEC source: 0001209191-06-007505 · doc4.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,556 Read SEC document |
| January 20, 2006 Filed Jan 24, 2006 20:55 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 6,289 | $57.04 | $358,724.56 |
DisclosureSEC source: 0001209191-06-004733 · doc4.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,334 Read SEC document |
| December 16, 2005 Filed Feb 14, 2007 21:18 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 270 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-07-010539 · doc5.xml · nonDerivative · entry 3 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,065 F2 · kind: Charitable gifts. Read SEC document |
| December 15, 2005 Filed Dec 19, 2005 22:03 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 5,000 | $56.14 | $280,700.00 |
DisclosureSEC source: 0001209191-05-064236 · doc4.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,045 Read SEC document |
| October 07, 2005 Filed Oct 11, 2005 16:37 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option 10/95 (right to buy) · Derivative | 27,728 | $0.00 Strike: $23.41 | $0.00 |
DisclosureSEC source: 0001209191-05-051821 · doc4.xml · derivative · entry 7 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,728 shares Expires 2005-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2005 Filed Oct 11, 2005 16:37 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 16,865 | $54.01 | $910,878.65 |
DisclosureSEC source: 0001209191-05-051821 · doc4.xml · nonDerivative · entry 2 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,045 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 2, 2005. Read SEC document |
| October 07, 2005 Filed Oct 11, 2005 16:37 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 27,728 | $23.41 | $649,043.16 |
DisclosureSEC source: 0001209191-05-051821 · doc4.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 2, 2005. Read SEC document |
| October 07, 2005 Filed Feb 14, 2007 21:18 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 410 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-07-010539 · doc5.xml · nonDerivative · entry 20 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 5,494 F3 · kind: These transactions involved gifts of securities by the reporting person's wife to his son and daughter. All three share the reporting person's household. The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| October 07, 2005 Filed Feb 14, 2007 21:18 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 2,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-07-010539 · doc5.xml · nonDerivative · entry 19 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 5,904 F1 · kind: These transactions involved gifts of securities by the reporting person to his wife, daughter, and son, all of whom share the reporting person's household. The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| October 07, 2005 Filed Feb 14, 2007 21:18 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 205 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-07-010539 · doc5.xml · nonDerivative · entry 15 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Indirect · by son Disclosed balance after: 2,824 F3 · kind: These transactions involved gifts of securities by the reporting person's wife to his son and daughter. All three share the reporting person's household. The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| October 07, 2005 Filed Feb 14, 2007 21:18 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 205 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-07-010539 · doc5.xml · nonDerivative · entry 14 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Indirect · by son Disclosed balance after: 2,619 F1 · kind: These transactions involved gifts of securities by the reporting person to his wife, daughter, and son, all of whom share the reporting person's household. The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| October 07, 2005 Filed Feb 14, 2007 21:18 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 205 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-07-010539 · doc5.xml · nonDerivative · entry 10 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Indirect · by daughter Disclosed balance after: 2,824 F3 · kind: These transactions involved gifts of securities by the reporting person's wife to his son and daughter. All three share the reporting person's household. The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| October 07, 2005 Filed Feb 14, 2007 21:18 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 205 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-07-010539 · doc5.xml · nonDerivative · entry 9 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Indirect · by daughter Disclosed balance after: 2,619 F1 · kind: These transactions involved gifts of securities by the reporting person to his wife, daughter, and son, all of whom share the reporting person's household. The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| October 07, 2005 Filed Feb 14, 2007 21:18 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 2,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-07-010539 · doc5.xml · nonDerivative · entry 2 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,335 F1 · kind: These transactions involved gifts of securities by the reporting person to his wife, daughter, and son, all of whom share the reporting person's household. The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| February 07, 2005 Filed Feb 15, 2005 22:25 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 6,000 | $56.00 | $336,000.00 |
DisclosureSEC source: 0000059478-05-000072 · doc4.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · President, US Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,182 Read SEC document |
| January 14, 2005 Filed Jan 18, 2005 19:48 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 5,600 | $56.79 | $318,024.00 |
DisclosureSEC source: 0000059478-05-000017 · doc4.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · President, US Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,452 Read SEC document |
| December 20, 2004 Filed Feb 14, 2005 23:45 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 270 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-05-000047 · doc5.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · President, US Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,582 Read SEC document |
| October 11, 2004 Filed Oct 13, 2004 16:35 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 16,000 | $0.00 Strike: $14.66 | $0.00 |
DisclosureSEC source: 0000059478-04-000164 · doc4.xml · derivative · entry 6 SANTINI GINO · CIK 0001276038 · President, US Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2004-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 11, 2004 Filed Oct 13, 2004 16:35 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 16,000 | $14.66 | $234,520.00 |
DisclosureSEC source: 0000059478-04-000164 · doc4.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · President, US Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2004 Filed Feb 14, 2007 21:18 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 344 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-07-010539 · doc5.xml · nonDerivative · entry 18 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 3,738 F3 · kind: These transactions involved gifts of securities by the reporting person's wife to his son and daughter. All three share the reporting person's household. The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| August 05, 2004 Filed Feb 14, 2007 21:18 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 1,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-07-010539 · doc5.xml · nonDerivative · entry 17 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 4,082 F1 · kind: These transactions involved gifts of securities by the reporting person to his wife, daughter, and son, all of whom share the reporting person's household. The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| August 05, 2004 Filed Feb 14, 2007 21:18 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 172 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-07-010539 · doc5.xml · nonDerivative · entry 13 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Indirect · by son Disclosed balance after: 2,414 F3 · kind: These transactions involved gifts of securities by the reporting person's wife to his son and daughter. All three share the reporting person's household. The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| August 05, 2004 Filed Feb 14, 2007 21:18 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 172 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-07-010539 · doc5.xml · nonDerivative · entry 12 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Indirect · by son Disclosed balance after: 2,242 F1 · kind: These transactions involved gifts of securities by the reporting person to his wife, daughter, and son, all of whom share the reporting person's household. The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| August 05, 2004 Filed Feb 14, 2007 21:18 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 172 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-07-010539 · doc5.xml · nonDerivative · entry 8 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Indirect · by daughter Disclosed balance after: 2,414 F3 · kind: These transactions involved gifts of securities by the reporting person's wife to his son and daughter. All three share the reporting person's household. The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| August 05, 2004 Filed Feb 14, 2007 21:18 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 172 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-07-010539 · doc5.xml · nonDerivative · entry 7 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Indirect · by daughter Disclosed balance after: 2,242 F1 · kind: These transactions involved gifts of securities by the reporting person to his wife, daughter, and son, all of whom share the reporting person's household. The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| August 05, 2004 Filed Feb 14, 2007 21:18 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 2,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-07-010539 · doc5.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,048 F1 · kind: These transactions involved gifts of securities by the reporting person to his wife, daughter, and son, all of whom share the reporting person's household. The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| March 11, 2004 Filed Mar 15, 2004 17:23 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 15,880 | $0.00 Strike: $12.31 | $0.00 |
DisclosureSEC source: 0000059478-04-000090 · doc4.xml · derivative · entry 7 SANTINI GINO · CIK 0001276038 · President, US Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,880 shares Expires 2004-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2004 Filed Mar 15, 2004 17:23 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 6,816 | $70.49 | $480,459.84 |
DisclosureSEC source: 0000059478-04-000090 · doc4.xml · nonDerivative · entry 2 SANTINI GINO · CIK 0001276038 · President, US Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,852 Read SEC document |
| March 11, 2004 Filed Mar 15, 2004 17:23 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 15,880 | $12.31 | $195,522.50 |
DisclosureSEC source: 0000059478-04-000090 · doc4.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · President, US Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2004 Filed Feb 19, 2004 20:15 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantEmployee stock option (right to buy) · Derivative | 80,000 | $0.00 Strike: $73.11 | $0.00 |
DisclosureSEC source: 0000059478-04-000079 · doc4.xml · derivative · entry 1 SANTINI GINO · CIK 0001276038 · President, US Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2014-02-14 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.